Eric Johnson, MD
Family Medicine · Mobile, ALNPI 1902812803
Payments from drug & device makers
Across 213 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$761
- Novo Nordisk$423
- AstraZeneca$349
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$268
- Pfizer$267
- Lilly USA, LLC$206
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,52097%
- Education$1053%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $761 |
| Novo Nordisk | 27 | $423 |
| AstraZeneca | 19 | $349 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $268 |
| Pfizer | 14 | $267 |
| Lilly USA, LLC | 14 | $206 |
| GSK | 10 | $159 |
| Astellas Pharma US Inc | 4 | $153 |
| Corium, LLC | 6 | $111 |
| Amgen | 7 | $101 |
| Daiichi Sankyo Inc. | 4 | $73 |
| Exact Sciences | 4 | $68 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $49 |
| Boehringer Ingelheim | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 3 | $44 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $32 |
| Novartis | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Theratechnologies Inc. | 1 | $30 |
| Merck | 2 | $30 |
| Johnson & Johnson | 2 | $28 |
| Ironwood Pharmaceuticals, Inc | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $19 |
| Eisai Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$3,625 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 202 | $256,986 |
| MounjaroTirzepatide | 147 | $160,250 |
| EliquisApixaban | 187 | $131,889 |
| FarxigaDapagliflozin Propanediol | 135 | $113,833 |
| JardianceEmpagliflozin | 98 | $96,229 |
| TrulicityDulaglutide | 74 | $86,768 |
| LinzessLinaclotide | 98 | $71,632 |
| XareltoRivaroxaban | 58 | $68,943 |
| RybelsusSemaglutide | 21 | $47,284 |
| TradjentaLinagliptin | 56 | $39,023 |
| MyrbetriqMirabegron | 43 | $36,869 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $35,158 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $22,449 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $22,228 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $20,528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $423 | $304,270223 claims |
| Lilly USA, LLCMounjaro, Trulicity | $206 | $247,018221 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $46 | $146,882170 claims |
| PfizerEliquis | $267 | $131,889187 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $349 | $128,280169 claims |
| Johnson & JohnsonXarelto, Invokana | $28 | $85,13270 claims |
| AbbVieLinzess | $761 | $71,63298 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $159 | $57,60783 claims |
| Astellas Pharma US IncMyrbetriq | $153 | $36,86943 claims |
| MerckJanuvia, Janumet Xr | $30 | $21,93527 claims |
| NovartisEntresto | $31 | $19,85726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Mobile
- Joel LaughlinMobile$75K
- Ashleigh Butts-WilkersonMobile$54K
- Anthony NguyenMobile$20K
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.